Volgen
José van der Hoorn
José van der Hoorn
Research Scientist/ project leader, TNO Metabolic Health Research, Leiden
Geverifieerd e-mailadres voor tno.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Mouse models for atherosclerosis and pharmaceutical modifiers
S Zadelaar, R Kleemann, L Verschuren, J de Vries-Van der Weij, ...
Arteriosclerosis, thrombosis, and vascular biology 27 (8), 1706-1721, 2007
6902007
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
AE van Herwaarden, E Wagenaar, CMM van der Kruijssen, ...
The Journal of clinical investigation 117 (11), 3583-3592, 2007
2602007
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin [S]
S Kühnast, JWA van der Hoorn, EJ Pieterman, AM van den Hoek, ...
Journal of lipid research 55 (10), 2103-2112, 2014
2272014
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
JWA van der Hoorn, W de Haan, JFP Berbée, LM Havekes, JW Jukema, ...
Arteriosclerosis, thrombosis, and vascular biology 28 (11), 2016-2022, 2008
2202008
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice
C Landlinger, MG Pouwer, C Juno, JWA van der Hoorn, EJ Pieterman, ...
European heart journal 38 (32), 2499-2507, 2017
2162017
Perfluoroalkyl sulfonates cause alkyl chain length–dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE* 3-Leiden CETP mice
S Bijland, PCN Rensen, EJ Pieterman, ACE Maas, JW van der Hoorn, ...
Toxicological Sciences 123 (1), 290-303, 2011
1452011
Remote ischaemic preconditioning by brief hind limb ischaemia protects against renal ischaemia-reperfusion injury: the role of adenosine
KE Wever, MC Warlé, FA Wagener, JW van der Hoorn, R Masereeuw, ...
Nephrology Dialysis Transplantation 26 (10), 3108-3117, 2011
1232011
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
W de Haan, J de Vries-van der Weij, JWA van der Hoorn, T Gautier, ...
Circulation 117 (19), 2515-2522, 2008
1122008
Autoantibodies against mannose-binding lectin in systemic lupus erythematosus
MA Seelen, LA Trouw, JWA van der Hoorn, FC Fallaux-Van Den Houten, ...
Clinical & Experimental Immunology 134 (2), 335-343, 2003
992003
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy
JW Jukema, JWA van der Hoorn
Expert opinion on pharmacotherapy 5 (2), 459-468, 2004
922004
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
S Kühnast, SJL van der Tuin, JWA van der Hoorn, JB van Klinken, B Simic, ...
European heart journal 36 (1), 39-50, 2015
892015
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE [S]
B Ason, JWA van der Hoorn, J Chan, E Lee, EJ Pieterman, KK Nguyen, ...
Journal of lipid research 55 (11), 2370-2379, 2014
732014
APOE* 3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome
AM van den Hoek, JWA van der Hoorn, AC Maas, RM van den Hoogen, ...
Diabetes, Obesity and Metabolism 16 (6), 537-544, 2014
662014
Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE* 3-Leiden. CETP mice
JFP Berbée, MC Wong, Y Wang, JWA van der Hoorn, PPSJ Khedoe, ...
The Journal of Nutritional Biochemistry 24 (8), 1423-1430, 2013
632013
Niacin reduces atherosclerosis development in APOE* 3Leiden. CETP mice mainly by reducing nonHDL-cholesterol
S Kühnast, MC Louwe, MM Heemskerk, EJ Pieterman, JB van Klinken, ...
PloS one 8 (6), e66467, 2013
582013
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta …
S Kühnast, M Fiocco, JWA van der Hoorn, HMG Princen, JW Jukema
European journal of pharmacology 763, 48-63, 2015
552015
Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein
J de Vries-van der Weij, W de Haan, L Hu, M Kuif, HLDW Oei, ...
Endocrinology 150 (5), 2368-2375, 2009
522009
Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE* 3Leiden mice without affecting liver or plasma triglyceride levels
JWA van der Hoorn, D Lindén, U Lindahl, MEA Bekkers, M Voskuilen, ...
British journal of pharmacology 162 (7), 1553-1563, 2011
492011
Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE* 3-Leiden. CETP mice
S Bijland, EJ Pieterman, ACE Maas, JWA van der Hoorn, MJ van Erk, ...
Journal of biological chemistry 285 (33), 25168-25175, 2010
472010
The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
JWA Van Der Hoorn, JW Jukema, LM Havekes, E Lundholm, G Camejo, ...
British Journal of Pharmacology 156 (7), 1067-1075, 2009
422009
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20